AKT1 and neoplasm: TA possesses the capability of inhibiting AKT, effectively suppressing the PI3K/AKT signaling pathway, triggering autophagy-mediated death in diverse tumor cells, and reversing acquired drug resistance, including but not limited to paclitaxel and sorafenib.